Dynavax Technologies Corporation (NasdaqGM: DVAX)
Health Care · Biotechnology · US
$—
— today · — 1Y
Dynavax Technologies Corporation (NasdaqGM: DVAX) operates in the Biotechnology industry within the Health Care sector.
trading between 9.20 and 15.73.
Tweenvest scores Dynavax Technologies Corporation across four factors: quality 70/100, value 42/100, growth 100/100. Its strongest factor is growth.
DVAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $330.51M
- P/E
- —
- EPS
- -0.36
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $15.73
- 52-week low
- $9.20
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 405
- Next earnings
- —
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.
- ISIN
- US2681582019
- Founded
- 1996
- Listed since
- Feb 19, 2004
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.26 | -1.70% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.02 | -0.73% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.48 | -0.87% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.02 | -1.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.08 | -1.02% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.71 | -5.11% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.